Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference

Assembly Biosciences NASDAQ: ASMB Chief Medical Officer Anuj Gaggar outlined the company's virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses.

MarketBeat • 18 hours ago

Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 14, 2026

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Study of the Liver (EASL) Congress taking place May 27-30, 2026, in Barcelona, Spain.

GlobeNewsWire • May 13, 2026

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, chief medical officer, will present during the Bank of America Securities 2026 Global Health Care Conference at 4:35 p.m. Pacific Time on May 13, 2026.

GlobeNewsWire • May 11, 2026

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the first quarter ended March 31, 2026, and recent highlights.

GlobeNewsWire • May 7, 2026

Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates

Assembly Biosciences (ASMB) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $1.17 per share a year ago.

Zacks Investment Research • May 7, 2026

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-primase inhibitor candidates, will be featured in multiple presentations, including one late-breaker, at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) taking place April 17-21, 2026, in Munich, Germany.

GlobeNewsWire • Apr 9, 2026

Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development

Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HDV candidate ABI-6250 are expected to initiate by end of 2026, with interim catalysts ahead. ABI-6250 aims to be the first oral HDV therapy, addressing an unmet need with positive phase 1a data and a favorable safety profile supporting daily dosing.

Seeking Alpha • Mar 20, 2026

Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 –

GlobeNewsWire • Mar 19, 2026

Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates

Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to a loss of $1.57 per share a year ago.

Zacks Investment Research • Mar 19, 2026